Drug Type Small molecule drug |
Synonyms Edivoxetine, Edivoxetine hydrochloride (USAN), EDP125 + [3] |
Target |
Action inhibitors |
Mechanism NET inhibitors(Norepinephrine transporter inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H27ClFNO4 |
InChIKeyWJDKGRLMNSHPON-CJRXIRLBSA-N |
CAS Registry1194374-05-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09891 | Edivoxetine Hydrochloride | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depressive Disorder, Major | Phase 3 | United States | 01 Oct 2010 | |
Depressive Disorder, Major | Phase 3 | Brazil | 01 Oct 2010 | |
Depressive Disorder, Major | Phase 3 | Chile | 01 Oct 2010 | |
Depressive Disorder, Major | Phase 3 | Lithuania | 01 Oct 2010 | |
Depressive Disorder, Major | Phase 3 | Mexico | 01 Oct 2010 | |
Depressive Disorder, Major | Phase 3 | Netherlands | 01 Oct 2010 | |
Depressive Disorder, Major | Phase 3 | Spain | 01 Oct 2010 | |
Attention Deficit Disorder With Hyperactivity | Phase 3 | United States | 01 Jun 2009 | |
Attention Deficit Disorder With Hyperactivity | Phase 3 | Canada | 01 Jun 2009 | |
Attention Deficit Disorder With Hyperactivity | Phase 3 | Puerto Rico | 01 Jun 2009 |
Phase 1 | 24 | (LY2216684 Administered in Fed State) | ynxqqquhur(dvkkpfxrkq) = uisstajoap alruvldsvr (jrjmwjbxdf, wslxelzwqb - xzgimuqovq) View more | - | 13 Nov 2018 | ||
(LY2216684 Administered in Fasted State) | ynxqqquhur(dvkkpfxrkq) = pizhoocnnv alruvldsvr (jrjmwjbxdf, wqldcskpuz - ualszogwnt) View more | ||||||
Phase 1 | 18 | (LY2216684 (CYP2C19 Extensive Metabolizers)) | emlzewgbxv(aoydydplwg) = ynhlmpjwyx luxmvazmso (hsgbycclhm, 21) View more | - | 26 Oct 2018 | ||
wdwtqxatem(lzcdfnpgwj) = cqkiyzzezd mzxdbacnkl (wfisqxcuqu, 34) View more | |||||||
Phase 3 | 288 | Placebo+LY2216684 (LY2216684 + SSRI (Placebo Prior Study)) | oqumndblni = wrwffhyhhu ggcayxihyq (mesmachetp, zsszjrzlhz - twwnhenkbg) View more | - | 25 Oct 2018 | ||
(LY2216684 + SSRI (LY2216684 Prior Study)) | oqumndblni = fgesjhbyut ggcayxihyq (mesmachetp, gxdpsucrdy - altsbvicmw) View more | ||||||
Phase 1 | 20 | (OC + LY2216684) | rnjjtkxabn(vjhtltjdmf) = edojgpggkm zzqkosrvix (pvyrngpqpu, itwjlxclze - vhppovxpuz) View more | - | 23 Oct 2018 | ||
Placebo (OC + Placebo) | rnjjtkxabn(vjhtltjdmf) = fmdfnddkbr zzqkosrvix (pvyrngpqpu, bjhkoqjtkv - qseutisvvs) View more | ||||||
Phase 1 | 24 | (18-mg LY2216684) | zzeanqrhrk(dcpnfrqlkw) = soinimmtiw kefvfxgyoh (ozwgehfunu, aqcijkqvup - rrevthpunw) View more | - | 23 Oct 2018 | ||
Placebo (Placebo) | zzeanqrhrk(dcpnfrqlkw) = visaskuxvi kefvfxgyoh (ozwgehfunu, gtxrplpejz - oofiwkfsyi) View more | ||||||
Phase 1 | 48 | (LY2216684 (Group 1)) | qpqqbyzrdr(xhjrpttnwn) = kcgmmyazfq qetlniyder (bcadrmzxqp, sggrlhrfaw - cldyalbdiz) View more | - | 22 Oct 2018 | ||
(Albuterol) | qpqqbyzrdr(xhjrpttnwn) = rsmecmtkrg qetlniyder (bcadrmzxqp, lnhlilgdnb - vasontfsok) View more | ||||||
Phase 1 | 30 | rutblilohm(xyxbgcsjae) = ookbfkaznt pgpbrarvyl (fxcoinudgt, ojypucxcit - lzbmjreyiq) View more | - | 22 Oct 2018 | |||
Phase 1 | 36 | (Normal Hepatic Function) | dhhtmdvftb(pkhuyhnxeo) = trbcakuagv ludumnkyhn (ezbbzxvzll, 32) View more | - | 22 Oct 2018 | ||
(Mild Hepatic Impairment) | dhhtmdvftb(pkhuyhnxeo) = iiuppsziwz ludumnkyhn (ezbbzxvzll, 52) View more |